Protein– tag –
-
Targeted Protein Degradation (TPD) Enters Decisive Clinical Phase, Evolving Beyond PROTACs to Multifunctional Therapeutics
European Biotechnology Magazine Europe Overview Targeted protein degradation (TPD) is poised for a major clinical breakthrough, with 2026 marking a decisive phase as a diverse pipeline of next-generation degraders, including molecular gl... -
GZL626, a Novel Molecular Glue Degrader for Androgen Receptor (AR/AR-V7), Overcomes Resistance in Advanced Prostate Cancer
bioRxiv Unknown Overview A preprint on bioRxiv describes the identification of GZL626, a novel small-molecule molecular glue degrader that induces proteasome-dependent degradation of both full-length androgen receptor (AR) and its splice... -
ChemRxiv Unveils AI Workflow for Structure-Aware Small-Molecule Drug Design: Integrating Agentic, Explainable, and Generative AI for Design to Prioritization
ChemRxiv Unknown Overview A preprint on ChemRxiv describes an innovative AI workflow for structure-aware small-molecule drug design, integrating agentic and explainable machine learning with generative molecular design. This system autom... -
Cytokine Co-Presentation on Targeted Lipid Nanoparticles Enhances In Vivo T Cell Engineering: IL-7 Co-Presentation Biases Functional mRNA Transfection Towards Splenic T Cells
PubMed (bioRxiv) Unknown Overview This research describes an enhanced lipid nanoparticle (LNP) design that co-presents interleukin-7 (IL-7) with anti-CD3 and anti-CD28 antibodies. This novel LNP significantly improves particle uptake and... -
Oregon State University Develops Novel Sugar-Coated Nanoparticle Therapy for Glioblastoma: Boosting Mouse Survival by 50%
Oregon State University via Medical Xpress USA Overview Researchers at Oregon State University have developed a new experimental glioblastoma treatment using sugar-coated nanoparticles to deliver genetic instructions that restore a tumor... -
Bora Biologics Expands US Biologics Manufacturing Capacity to 20,000 Liters with New Rockville, Maryland Site
PharmaSource USA Overview Bora Biologics has expanded its U.S. drug substance manufacturing platform by adding a new site in Rockville, Maryland. This expansion increases its single-use bioreactor capacity to 20,000 liters, with scalabil... -
Cytovance Biologics Enhances Biologics Manufacturing Process Development with Perfusion Capabilities to Boost Productivity
Cytovance Biologics USA Overview Cytovance Biologics, a CDMO, has expanded its upstream process development services by integrating perfusion capabilities. This technological addition enables higher productivity, extended cell culture du... -
Monte Rosa Therapeutics’ NEK7 Molecular Glue Degrader MRT-8102/8120 Shows 85% CRP Reduction in Cardiovascular Risk Patients in Positive Phase 1 Interim Data
AllMind AI News USA Overview Monte Rosa Therapeutics reported positive interim Phase 1 data for its NEK7-directed molecular glue degrader, MRT-8102/8120, demonstrating an 85% median reduction in C-reactive protein (CRP) over 4 weeks in c... -
Pfizer and Arvinas’ Veppanu (vepdegestrant) Gains FDA Approval, Revolutionizing ESR1-Mutated Advanced Breast Cancer as First PROTAC
DCAT Value Chain Insights USA Overview In 2026, Pfizer and Arvinas' Veppanu (vepdegestrant) received FDA approval for advanced breast cancer with ESR1 mutations, becoming the first FDA-approved PROTAC. This drug offers a groundbreaking o... -
Exponential Progression in Targeted Protein Degradation (TPD) Drug Discovery: New Modality Accelerates Drug Development
MarinBio USA Overview MarinBio published an article highlighting the exponential progression in Targeted Protein Degradation (TPD) drug discovery, establishing it as a primary, accelerating modality in novel drug development. TPD technol...
